SAM
COGT icon

SEB Asset Management’s Cogent Biosciences COGT Stock Holding History

SEB Asset Management’s Portfolio COGT Stock Details COGT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$8.83M Buy
228,093
+63,656
+39% +$2.23M 0.03% 364
2026
Q1 		$6.33M Buy
+164,437
New +$6.07M 0.03% 412

Other funds holding COGT

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.51B AUM 546.08% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Lord, Abbett & Co
Lord, Abbett & Co Jersey City, New Jersey $34.9B AUM 72.7% 1-Year Est. Return

SEB Asset Management's COGT Position: Q2 2026 in Review

SEB Asset Management increased its Cogent Biosciences (COGT) stake by 39% in Q2 2026, buying an estimated $2.23M and bringing the position to 228,093 shares worth $8.83M. The position accounts for 0.03% of the portfolio, ranked #364.

SEB Asset Management first reported a position in COGT in Q1 2026 and has held it in 2 quarters since. 290 funds tracked by Wall St. Rank hold COGT as of Q2 2026.

  • SEB Asset Management held 228,093 shares of Cogent Biosciences worth $8.83M as of Q2 2026.
  • SEB Asset Management bought 63,656 Cogent Biosciences shares in Q2 2026, an estimated $2.23M.
  • Cogent Biosciences made up 0.03% of SEB Asset Management's portfolio in Q2 2026, its #364 holding.
  • SEB Asset Management first reported a position in Cogent Biosciences in Q1 2026 and has held it in 2 quarters since.
  • 290 funds tracked by Wall St. Rank held Cogent Biosciences as of Q2 2026.

Based on SEB Asset Management's 13F filing for Q2 2026, filed 4 Aug 2026.